Dificid Granule, For Suspension
NDC Package 52015-700-22
Package Information
Dificid (fidaxomicin) granules is a medication used to treat a severe intestinal condition (C. This formulation utilizes a granule, for suspension delivery system. Marketed by Merck Sharp & Dohme Llc, this product is identified by NDC 52015-700 and is authorized under FDA application NDA213138.
Identification & Billing
- RxCUI: 1111106 - fidaxomicin 200 MG Oral Tablet
- RxCUI: 1111110 - DIFICID 200 MG Oral Tablet
- RxCUI: 1111110 - fidaxomicin 200 MG Oral Tablet [Dificid]
- RxCUI: 1111110 - Dificid 200 MG Oral Tablet
- RxCUI: 2279843 - fidaxomicin 40 MG/mL Oral Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 52015 - Merck Sharp & Dohme Llc
- 52015-700 - Dificid
- 52015-700-22 - 1 POUCH in 1 CARTON / 1 BOTTLE, GLASS in 1 POUCH (52015-700-23) / 150 mL in 1 BOTTLE, GLASS (52015-700-21)
- 52015-700 - Dificid
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 52015-700-22 identifies a specific commercial package of 1 pouch in 1 carton / 1 bottle, glass in 1 pouch (52015-700-23) / 150 ml in 1 bottle, glass (52015-700-21) of Dificid, a human prescription drug labeled by Merck Sharp & Dohme Llc. This granule, for suspension is formulated for oral use and contains fidaxomicin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Merck Sharp & Dohme Llc on February 18, 2020. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat a severe intestinal condition (C. difficile-associated diarrhea) due to a certain type of bacteria. This condition may rarely occur after taking antibiotics. Symptoms include diarrhea that doesn't stop, stomach/abdominal pain or cramping, and blood/mucus in your stool. Fidaxomicin is known as a macrolide antibiotic. It works by stopping the growth of this bacteria. This antibiotic works in the intestines and is not absorbed by your body. It should only be used to treat this type of intestinal bacterial infection. It will not work for other types of infections, including viral infections (such as common cold, flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.
How is this Merck Sharp & Dohme Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 52015070022. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.